Manila Times Business
Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL
New Clinical Data, Patient Reported Outcomes, Real-World Utilization, and Comparative-Effectiveness Models to be Featured in Four Oral and One Poster Presentation PRINCETON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced new data further defining the potential of mogamulizumab in the treatment of relapsed or refractory mycosis fungoides and Sézary syndrome, two subtypes of cutaneous T-cell lymphoma, will be
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
The ChariTree Foundation Calls for More Outdoor Learning Opportunities for Children in the Age of AI
Just now
Budweiser China Co-Hosts Global Night-Time Economy Dialogue in Shanghai, Highlighting Multinational Companies’ Role in Urban Consumption Growth
Just now
Completion of the Sale of the Share of Saare Kala Tootmine OÜ
Just now
Shufti Ranked as a Leader in G2’s Summer 2026 Identity Verification Grid® Report
Just now